Fecal microbiota transplantation to prevent acute graft-versus-host disease: pre-planned interim analysis of donor effect

Nature·Jan 25

✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source

Research is being conducted on the use of fecal microbiota transplantation to prevent acute graft-versus-host disease, with a focus on the impact of donor factors. The study of microbiome dysbiosis and its modulation is also being explored in relation to cancer development, chemotherapy resistance, and hematopoietic stem cell transplantation outcomes. The potential of fecal microbiota transplantation to aid in healing after stem cell transplantation is being investigated.

Full coverage

Microbiome dysbiosis and its modulation in cancer development, prevention and therapy

Frontiers·Jun 17

Donor factors influence success of fecal microbiota transplant

Fred Hutchinson Cancer Center·Mar 21

Microbiome dysbiosis and chemotherapy resistance in acute myeloid leukemia (AML) | npj Biofilms and Microbiomes

Nature·Dec 22

Comprehensive management of hematopoietic stem cell transplantation complications: from infection prevention to immune microenvironment reconstruction

Frontiers·Feb 23

Fecal Microbiota Transplantation Following ASCT

The ASCO Post·Jan 30

The Impact of Microbiome Dysbiosis on Hematopoietic Stem Cell Transplantation Outcomes: A Review Article

Cureus·Jul 6

Microbiotoxicity: an under-recognised player in drug efficacy, toxicity, and health outcomes

Nature·Dec 23

Could fecal microbiota transplantation help patients heal after stem cell transplantation?

Fred Hutchinson Cancer Center·Jan 25

View original report at Nature ↗

Fetching the latest headlines…